Trials / Completed
CompletedNCT02078102
A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
A Phase II Trial of Prostaglandin E2 Inhibition, Using Meloxicam, Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Sherif S. Farag · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The trial is an open label Simon optimal two-stage Phase II trial of fixed doses of oral meloxicam and subcutaneous filgrastim to assess the safety and efficacy in mobilizing autologous peripheral blood stem cells (PBSC) from multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) patients planning to undergo high-dose chemotherapy with stem cell support. Clinical data regarding the cellular composition and function of the graft mobilized by this combination will be obtained.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Meloxicam | 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food. |
| DRUG | Filgrastim | Filgrastim will be subcutaneously injected in one or two sites at home. |
Timeline
- Start date
- 2014-03-11
- Primary completion
- 2018-11-06
- Completion
- 2019-02-21
- First posted
- 2014-03-05
- Last updated
- 2021-02-21
- Results posted
- 2021-02-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02078102. Inclusion in this directory is not an endorsement.